Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-6)

Sum=0

Jun 24, 2025 (publication date) through Jun 20, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Jun 24, 2025; 16(6): 108113
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.108113

Table 5 Androgen deprivation therapy duration by vitamin D level and cancer stage

Vitamin D level group	Duration of ADT therapy (months), median (IQR)
Overall	18 (10-33.5)
< 30 ng/mL	18 (10-41)
30-49 ng/mL	18 (8-30)
≥ 50 ng/mL	20 (14-28)
Stage 2 and 3	14 (8-20)
Stage 4	21 (12-39)

IQR: Interquartile range; ADT: Androgen deprivation therapy.

Citation: Hasan N, Rafizadeh D, Gibson S, Kaakour D, Lee B, Khaleghi B, Yazdanpanah O, Rezazadeh Kalebasty A. Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy. World J Clin Oncol 2025; 16(6): 108113
URL: https://www.wjgnet.com/2218-4333/full/v16/i6/108113.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i6.108113